Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Australia & Oceania has been steadily growing in recent years, driven by various factors such as increasing prevalence of autoimmune diseases and rising demand for organ transplantation.
Customer preferences: Patients suffering from autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis are the primary consumers of immunosuppressants in Australia & Oceania. Additionally, there is a growing demand for immunosuppressants among patients who have undergone organ transplantation to prevent rejection of the transplanted organ.
Trends in the market: One of the major trends in the Immunosuppressants market in Australia & Oceania is the increasing use of biologics as immunosuppressants. Biologics are highly effective in treating autoimmune diseases and have fewer side effects compared to traditional immunosuppressants. The market is also witnessing a trend towards personalized medicine, with healthcare providers increasingly tailoring treatment plans based on individual patient needs.
Local special circumstances: Australia & Oceania has a relatively small population compared to other regions, which has resulted in limited market opportunities for pharmaceutical companies operating in the region. However, the region has a highly developed healthcare infrastructure, which has facilitated the adoption of advanced medical technologies and treatments.
Underlying macroeconomic factors: The growing prevalence of autoimmune diseases and rising demand for organ transplantation are key drivers of the Immunosuppressants market in Australia & Oceania. Additionally, increasing healthcare expenditure and rising disposable incomes have contributed to the growth of the market. However, the high cost of biologics and other advanced immunosuppressants may hinder market growth in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
